For the previous a number of years, the marketplace has related Eli Lilly (LLY +1.56%) with something: weight problems. Its blockbuster weight-loss drug Zepbound and diabetes remedy Mounjaro have remodeled the corporate, serving to power annual income from $34.1 billion in 2023 to greater than $65.2 billion in 2025.
However it will be silly to forget about the elephant within the room: What is subsequent after GLP-1 and weight problems remedies? Lilly could have simply equipped a part of the solution.
Symbol supply: Getty Pictures.
The corporate just lately introduced 3 separate acquisitions at the similar day, agreeing to obtain Curevo, LimmaTech Biologics, and Vaccine Corporate in a coordinated push into infectious illness prevention. The offers may just in the end price Lilly greater than $3.8 billion, together with milestone bills.
A raffle on prevention
The 3 acquisitions goal very other infectious illness alternatives.
Cuervo
Curevo is creating amezosvatein, a next-generation shingles vaccine recently in section 2 trying out. In head-to-head research, the vaccine reportedly matched the immune reaction of the GSK Shingrix vaccine (the present usual of maintain shingles prevention) whilst decreasing unintended effects reminiscent of fatigue, chills, and injection-site ache by way of greater than 50%.
Now, Shingrix recently generates round $4.8 billion in annual gross sales, so even a rather small proportion of that marketplace might be significant. If Curevo’s vaccine in the end captured simply 10% of the marketplace, you would be having a look at round $480 million in annual gross sales.
LimmaTech
LimmaTech is creating vaccines towards bacterial pathogens, together with Staphylococcus aureus, gonorrhea, and chlamydia. Those sicknesses are changing into increasingly more tricky to regard as antimicrobial resistance continues to upward push. The chance right here might be slightly vital.
For standpoint, Merck‘s Gardasil (the pharma large’s HPV vaccine) generated greater than $5.2 billion in gross sales in 2025. Whilst it is a ways too early to mission identical effects for LimmaTech’s systems, a a hit vaccine towards gonorrhea, chlamydia, or drug-resistant Staphylococcus aureus may just probably generate masses of thousands and thousands to a number of billion greenbacks in annual income, specifically as antibiotic resistance turns into a rising world well being fear.
Vaccine Corporate
Vaccine Corporate is creating vaccine era to stop viral infections, together with the ones brought about by way of the Epstein-Barr virus (EBV), which has been connected to a couple of sclerosis and a number of other cancers.
This may occasionally in truth be the biggest industrial alternative of the 3 acquisitions. The reason being that EBV infects more or less 90% to 95% of adults international and has been connected now not best to infectious mononucleosis but additionally to a couple of sclerosis, nasopharyngeal most cancers, Hodgkin lymphoma, and a number of other different cancers.
The a couple of sclerosis marketplace by myself is already valued at greater than $29 billion. Medication reminiscent of Ocrevus and Kesimpta each and every produce billions in once a year income. If researchers in the end turn out that fighting EBV an infection reduces the chance of creating MS, an efficient EBV vaccine may just deal with a illness burden price tens of billions of bucks every year.
The weight problems marketplace may not develop ceaselessly
Lilly stays exceptionally well-positioned in weight problems. Analysts nonetheless be expecting Zepbound and Mounjaro to generate tens of billions of bucks in annual income over the approaching decade. But control understands an excessively actual inconvenient fact: No pharmaceutical franchise lasts ceaselessly. Patent expirations sooner or later arrive. Festival emerges. New applied sciences disrupt outdated markets.
As of late’s Exchange
(1.56%) $17.66
Present Worth
$1149.08
Key Knowledge Issues
Marketplace Cap
$1.1T
Day’s Vary
$1143.80 – $1182.23
52wk Vary
$623.78 – $1182.23
Quantity
206.9K
Avg Vol
3.1M
Gross Margin
82.83%
Dividend Yield
0.57%
That is why Lilly has spent the previous a number of years aggressively obtaining long term expansion platforms. Along with those infectious illness offers, the corporate has just lately got corporations enthusiastic about gene enhancing, heart problems, irritation, neuroscience, genetic medication, and oncology.
The infectious illness acquisitions merely are compatible that trend. Put merely, Lilly seems to be construction solely new expansion engines that would generate income way past the weight problems growth.
Prevention and earnings
What makes those newest offers specifically attention-grabbing is they focal point on prevention. Traditionally, pharmaceutical corporations have generated monumental income treating continual sicknesses when they broaden. Vaccines and preventive medications can occasionally do away with the ones sicknesses ahead of they happen.
Lilly’s clinical management explicitly highlighted rising proof linking commonplace infections to long-term prerequisites, together with neurological illness, most cancers, infertility, stroke, and dementia. The corporate additionally pointed to antimicrobial resistance as a rising world danger that would building up the worth of vaccine-based prevention methods.
Certainly, that is an excessively other funding thesis than weight problems. As an alternative of serving to sufferers organize continual prerequisites, Lilly is making an investment in applied sciences designed to stop some sicknesses from happening within the first position. Whether or not those particular systems prevail stays unsure. Maximum are nonetheless early-stage property. However make no mistake: Those acquisitions don’t seem to be 3 remoted offers.
Lilly’s weight problems franchise would possibly dominate headlines nowadays. But control seems to be getting ready for a long term the place the corporate’s expansion depends upon a much wider portfolio of treatments, vaccines, and preventive medications. The weight problems growth made Lilly one of the crucial treasured healthcare corporations on the planet. Those infectious illness acquisitions recommend control is already making plans for what comes subsequent.
